Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 16/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004323 | 1.00 | TACR1 (0.42) | TACR1SLC6A4KCNH2SCN9A | |
| Hydrochloric Acid SCHEMBL4008396 | 0.99 | TACR1 (0.41) | TACR1SLC6A4KCNH2SCN9A | |
| SCHEMBL4967490 | 0.89 | TACR1 (0.46) | TACR1SLC6A4 | |
| SCHEMBL4006579 | 0.89 | TACR1 (0.46) | TACR1SLC6A4 | |
| Hydrochloric Acid SCHEMBL4004263 | 0.88 | TACR1 (0.45) | TACR1SLC6A4 | |
| SCHEMBL4005877 | 0.88 | TACR1 (0.52) | TACR1SLC6A4 | |
| SCHEMBL4967825 | 0.88 | TACR1 (0.52) | TACR1SLC6A4 | |
| SCHEMBL4008351 | 0.88 | TACR1 (0.47) | TACR1SLC6A4KCNH2 | |
| SCHEMBL4964048 | 0.88 | TACR1 (0.47) | TACR1SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL4005504 | 0.87 | TACR1 (0.51) | TACR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957450-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | claimed |
| WO-2007063009-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | claimed |
| US-20070129419-A1 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | claimed |
| EP-1957450-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007063009-A1 | SEROTONIN TRANSPORTER (SERT) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129419-A1 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129419-A1 | Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety | SLC6A4, SLC6A2, SLC6A3 | TACR1 171/4885SLC6A4 1/4885KCNH2 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.